Candel Therapeutics, Inc. (CADL)
6.20
-2.19
(-26.10%)
USD |
NASDAQ |
Nov 13, 16:00
6.05
-0.15
(-2.42%)
After-Hours: 19:59
Candel Therapeutics Shareholders Equity (Quarterly) : 131.59M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 131.59M |
| June 30, 2026 | 126.13M |
| March 31, 2026 | 138.03M |
| December 31, 2025 | 51.92M |
| September 30, 2025 | 80.12M |
| June 30, 2025 | 90.21M |
| March 31, 2025 | 74.68M |
| December 31, 2024 | 66.33M |
| September 30, 2024 | -15.26M |
| June 30, 2024 | -9.972M |
| March 31, 2024 | 5.979M |
| December 31, 2023 | 12.74M |
| Date | Value |
|---|---|
| September 30, 2023 | 23.02M |
| June 30, 2023 | 30.77M |
| March 31, 2023 | 39.65M |
| December 31, 2022 | 47.71M |
| September 30, 2022 | 52.13M |
| June 30, 2022 | 60.07M |
| March 31, 2022 | 63.76M |
| December 31, 2021 | 64.14M |
| September 30, 2021 | 62.99M |
| June 30, 2021 | 5.885M |
| March 31, 2021 | 21.56M |
| December 31, 2020 | 25.50M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Oragenics, Inc. | 1.092M |
| Arcturus Therapeutics Holdings, Inc. | 168.73M |
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 211.11M |
| Total Liabilities (Quarterly) | 79.52M |
| Debt to Equity Ratio | 0.3782 |
| Current Ratio | 7.571 |
| Net Debt Paydown Yield | -1.01% |